secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2026-05-15T20:41:12+00:00
Accession:  0001213900-26-057876
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma Q2 2026: $5.6M H1 LYMPHIR revenue, 80% gross margins; raises $36.5M at Citius Oncology
--------------------------------------------------------------------------------

- Net product revenue $1.7M in Q2 (launch quarter); $5.6M in H1 2026 vs. zero a year ago.
- Payer coverage near 100% of commercial lives; 83% of target accounts on formulary or in review.
- Citius Oncology secured up to $36.5M debt/equity; Citius Pharma raised $5M direct offering.
- Net loss $21.2M in Q2 ($0.95/share) vs. $10.9M a year ago; includes $19.7M CMO cancellation charge.
- First LYMPHIR shipment to Europe via Uniphar; positive Phase 1 combo data with pembrolizumab and pre-CAR-T.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/0001213900-26-057876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/ea0291037-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-057876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer